Related references
Note: Only part of the references are listed.The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia
Ghayas C. Issa et al.
NATURE (2023)
Blinatumomab Added to Chemotherapy in Infant Lymphoblastic Leukemia
Inge M. van der Sluis et al.
NEW ENGLAND JOURNAL OF MEDICINE (2023)
Cell Cycle-Dependent Transcription: The Cyclin Dependent Kinase Cdk1 Is a Direct Regulator of Basal Transcription Machineries
Jorrit M. Enserink et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)
MBD3 promotes hepatocellular carcinoma progression and metastasis through negative regulation of tumour suppressor TFPI2
Weiwei Yan et al.
BRITISH JOURNAL OF CANCER (2022)
New kinase and HDAC hybrid inhibitors: recent advances and perspectives
Karoline Waitman et al.
FUTURE MEDICINAL CHEMISTRY (2022)
Immunomodulatory properties of HDAC6 inhibitors in cancer diseases: New chances for sophisticated drug design and treatment optimization
Bernhard Biersack et al.
SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY (2022)
FLT3 inhibitor lestaurtinib plus chemotherapy for newly diagnosed KMT2A-rearranged infant acute lymphoblastic leukemia: Children's Oncology Group trial AALL0631
Patrick A. Brown et al.
LEUKEMIA (2021)
ARID4B Knockdown Suppresses PI3K/AKT Signaling and Induces Apoptosis in Human Glioma Cells
Siou-Min Luo et al.
ONCOTARGETS AND THERAPY (2021)
Differentiation of fetal hematopoietic stem cells requires ARID4B to restrict autocrine KITLG/KIT-Src signaling
In-Chi Young et al.
CELL REPORTS (2021)
Arid4b alters cell cycle and cell death dynamics during mouse embryonic stem cell differentiation
Gozde Guven et al.
TURKISH JOURNAL OF BIOLOGY (2021)
ARID4B is critical for mouse embryonic stem cell differentiation towards mesoderm and endoderm, linking epigenetics to pluripotency exit
Nihal Terzi Cizmecioglu et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2020)
A CRISPR Competition Assay to Identify Cancer Genetic Dependencies
Vishruth Girish et al.
BIO-PROTOCOL (2020)
Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study
Rob Pieters et al.
JOURNAL OF CLINICAL ONCOLOGY (2019)
Identification of the PTEN-ARID4B-PI3K pathway reveals the dependency on ARID4B by PTEN-deficient prostate cancer
Ray-Chang Wu et al.
NATURE COMMUNICATIONS (2019)
The HDAC inhibitor panobinostat (LBH589) exerts in vivo anti-leukaemic activity against MLL-rearranged acute lymphoblastic leukaemia and involves the RNF20/RNF40/WAC-H2B ubiquitination axis
P. Garrido Castro et al.
LEUKEMIA (2018)
A CRISPR screen identifies CDK7 as a therapeutic target in hepatocellular carcinoma
Cun Wang et al.
CELL RESEARCH (2018)
Overexpression of ARID4B predicts poor survival in patients with hepatocellular carcinoma
Rongchang Wang et al.
HUMAN PATHOLOGY (2018)
Selective DOT1L, LSD1, and HDAC Class I Inhibitors Reduce HOXA9 Expression in MLL-AF9 Rearranged Leukemia Cells, But Dysregulate the Expression of Many Histone-Modifying Enzymes
Ryan Lillico et al.
JOURNAL OF PROTEOME RESEARCH (2018)
How BMP-2 induces EMT and breast cancer stemness through Rb and CD44?
Guanglin Zhang et al.
CELL DEATH & DISEASE (2018)
Chronic myeloid leukaemia cells require the bone morphogenic protein pathway for cell cycle progression and self-renewal
Parto Toofan et al.
CELL DEATH & DISEASE (2018)
ARID4B is a good biomarker to predict tumour behaviour and decide WHO grades in gliomas and meningiomas
Wen-Chiuan Tsai et al.
JOURNAL OF CLINICAL PATHOLOGY (2017)
Cornerstones of CRISPR-Cas in drug discovery and therapy
Christof Fellmann et al.
NATURE REVIEWS DRUG DISCOVERY (2017)
Mbd3/NuRD controls lymphoid cell fate and inhibits tumorigenesis by repressing a B cell transcriptional program
Stephen J. Loughran et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
Genome-scale CRISPR-Cas9 knockout and transcriptional activation screening
Julia Joung et al.
NATURE PROTOCOLS (2017)
Clinical significance linked to functional defects in bone morphogenetic protein type 2 receptor, BMPR2
Myung-Jin Kim et al.
BMB REPORTS (2017)
BMP-2 induces EMT and breast cancer sternness through Rb and CD44
Peide Huang et al.
CELL DEATH DISCOVERY (2017)
Emerging roles of the bone morphogenetic protein pathway in cancer: potential therapeutic target for kinase inhibition
Pawina Jiramongkolchai et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
Role of the bone morphogenic protein pathway in developmental haemopoiesis and leukaemogenesis
Parto Toofan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2016)
CBP/p300 acetyltransferase activity in hematologic malignancies
Ritika Dutta et al.
MOLECULAR GENETICS AND METABOLISM (2016)
CRISPR knockout screening outperforms shRNA and CRISPRi in identifying essential genes
Bastiaan Evers et al.
NATURE BIOTECHNOLOGY (2016)
MBD3 mediates epigenetic regulation on EPAS1 promoter in cancer
Jie Cui et al.
TUMOR BIOLOGY (2016)
High-quality ChIP-seq analysis of MBD3 in human breast cancer cells
Takashi Shimbo et al.
GENOMICS DATA (2016)
Molecular mechanisms of MLL-associated leukemia
Akihiko Yokoyama
INTERNATIONAL JOURNAL OF HEMATOLOGY (2015)
Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains
Junwei Shi et al.
NATURE BIOTECHNOLOGY (2015)
Acute Lymphoblastic Leukemia in Children
Stephen P. Hunger et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The role of the bone morphogenetic proteins in leukaemic stem cell persistence
Parto Toofan et al.
BIOCHEMICAL SOCIETY TRANSACTIONS (2014)
Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells
Ophir Shalem et al.
SCIENCE (2014)
The new frontier of genome engineering with CRISPR-Cas9
Jennifer A. Doudna et al.
SCIENCE (2014)
A role for BMP-induced homeobox gene MIXL1 in acute myelogenous leukemia and identification of type I BMP receptor as a potential target for therapy
Aaron Raymond et al.
ONCOTARGET (2014)
MAGeCK enables robust identification of essential genes from genome-scale CRISPR/Cas9 knockout screens
Wei Li et al.
GENOME BIOLOGY (2014)
Bone morphogenetic proteins regulate differentiation of human promyelocytic leukemia cells
Iva Topic et al.
LEUKEMIA RESEARCH (2013)
RUNX1 Is a Key Target in t(4;11) Leukemias that Contributes to Gene Activation through an AF4-MLL Complex Interaction
Adam C. Wilkinson et al.
CELL REPORTS (2013)
MBD3 Localizes at Promoters, Gene Bodies and Enhancers of Active Genes
Takashi Shimbo et al.
PLOS GENETICS (2013)
Connectivity mapping identifies HDAC inhibitors for the treatment of t(4;11)-positive infant acute lymphoblastic leukemia
D. J. P. M. Stumpel et al.
LEUKEMIA (2012)
Allelic Variation and Differential Expression of the mSIN3A Histone Deacetylase Complex Gene Arid4b Promote Mammary Tumor Growth and Metastasis
Scott F. Winter et al.
PLOS GENETICS (2012)
MLL-Rearranged Leukemia Is Dependent on Aberrant H3K79 Methylation by DOT1L
Kathrin M. Bernt et al.
CANCER CELL (2011)
Mbd3/NURD Complex Regulates Expression of 5-Hydroxymethylcytosine Marked Genes in Embryonic Stem Cells
Ozlem Yildirim et al.
CELL (2011)
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber et al.
NATURE (2011)
Gene expression profiling-based dissection of MLL translocated and MLL germline acute lymphoblastic leukemia in infants
Ronald W. Stam et al.
BLOOD (2010)
An overview of Cdk1-controlled targets and processes
Jorrit M. Enserink et al.
CELL DIVISION (2010)
H3K79 Methylation Profiles Define Murine and Human MLL-AF4 Leukemias
Andrei V. Krivtsov et al.
CANCER CELL (2008)
MLL translocations, histone modifications and leukaemia stem-cell development
Andrei V. Krivtsov et al.
NATURE REVIEWS CANCER (2007)
D-HPLC analysis of the entire FLT3 gene in MLL rearranged and hyperdiploid acute lymphoblastic leukemia
Ronald W. Stam et al.
HAEMATOLOGICA (2007)
Prognostic significance of high-level FLT3 expression in MLL-rearranged infant acute lymphoblastic leukemia
Ronald W. Stam et al.
BLOOD (2007)
Protein arginine-methyltransferase-dependent oncogenesis
Ngai Cheung et al.
NATURE CELL BIOLOGY (2007)
A treatment protocol for infants younger than 1 year with acute lymphoblastic leukaemia (Interfant-99): an observational study and a multicentre randomised trial
Rob Pieters et al.
LANCET (2007)
Molecular regulation of H3K4 trimethylation by ASH2L, a shared subunit of MLL complexes
Melissa M. Steward et al.
NATURE STRUCTURAL & MOLECULAR BIOLOGY (2006)
Targeting FLT3 in primary MLL-gene-rearranged infant acute lymphoblastic leukemia
RW Stam et al.
BLOOD (2005)
Physical association and coordinate function of the H3K4 methyltransferase MLL1 and the H4K16 acetyltransferase MOF
YL Dou et al.
CELL (2005)
Definitive hematopoiesis requires the mixed-lineage leukemia gene
P Ernst et al.
DEVELOPMENTAL CELL (2004)
Genetic and epigenetic analyses of MBD3 in colon and lung cancer
Y Zhu et al.
BRITISH JOURNAL OF CANCER (2004)
Identification and characterization of three new components of the mSin3A corepressor complex
TC Fleischer et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Novel SWI/SNF chromatin-remodeling complexes contain a mixed-lineage leukemia chromosomal translocation partner
ZQ Nie et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
Inhibition of FLT3 in MLL: Validation of a therapeutic target identified by gene expression based classification
SA Armstrong et al.
CANCER CELL (2003)
The druggable genome
AL Hopkins et al.
NATURE REVIEWS DRUG DISCOVERY (2002)
The role of MLL in hematopoiesis and leukemia
P Ernst et al.
CURRENT OPINION IN HEMATOLOGY (2002)
MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia
SA Armstrong et al.
NATURE GENETICS (2002)
Share Paper
